<DOC>
	<DOC>NCT01046630</DOC>
	<brief_summary>The purpose of this study is to determine the effect of a single dose infusion of AZD 6765 compared with placebo and ketamine on the blood oxygen level dependent signal using fMRI (functional Magnetic Resonance Imaging) in depressed subjects.</brief_summary>
	<brief_title>Study Where Pharmaco Magnetic Resonance Imaging (MRI) Effects of AZD6765 Will be Compared to Placebo in Depressive Male and Female Subjects</brief_title>
	<detailed_description />
	<mesh_term>Ketamine</mesh_term>
	<criteria>Documented clinical diagnosis meeting criteria from the DSMIV by structured clinical interview,major depressive disorder, single episode or recurrent Outpatient status at screening and at randomisation A major depression disorder which has a major impact on the subjects current psychiatric status Subjects not allowed to use mood stabilizers, antidepressants or other antipsychotic or psychoactive drugs Subjects with lifetime history of schizophrenia, bipolar, psychosis and psychotic depression</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Phase I</keyword>
	<keyword>BOLD signal</keyword>
	<keyword>fMRI</keyword>
	<keyword>AZD6765</keyword>
	<keyword>BOLD signal measured by fMRI</keyword>
</DOC>